Lilly

LILLY PULITZER UNVEILS NEW LOGO FOR FIRST TIME IN FIFTEEN YEARS AS THEY ROLL OUT A MODERNIZED BRAND REFRESH

Retrieved on: 
Donnerstag, Mai 9, 2024
Lilly, Shoe, PALM, Partnership, Optimism, Lilly Pulitzer, Female, Pharmaceutical industry

PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- Lilly Pulitzer has refreshed their signature look. The iconic Palm Beach brand is unveiling a new logo for the first time in over fifteen years, which is kicking off what CEO Michelle Kelly is calling a "brand refresh" and builds on the brand's modernization strategy. As they continue to celebrate their 65th anniversary this year, the new logo has debuted on the brand's newest store in Rhode Island and will begin to make its way to more storefronts starting this summer.

Key Points: 
  • To honor Lilly Pulitzer's 65th Anniversary, the brand launches a modernized look inspired by their heritage.
  • PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- Lilly Pulitzer has refreshed their signature look.
  • In partnership with a collective of female creatives including Paula Scher from Pentagram, Lilly Pulitzer tapped into their rich heritage to create a new evolution of their brand identity.
  • "We want new, powerful branding that is as identifiable, confident yet playful as the Lilly brand is today."

ProQR Announces First Quarter 2024 Operating and Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
EON, Trident, Annual general meeting, Research, Partnership, Doctor of Philosophy, Webcast, Biomarker, Knowledge, Cholestasis, NTCP, RNA editing, Oncology, European Patent Convention, Oligonucleotide, Serum, Lilly, Eli Lilly and Company, Ribose, Pseudouridine, Poster, Alnylam Pharmaceuticals, Eli Lilly, RNA, Exercise, NHP, Clinical trial, ProQR, ADAR, B4GALT1, Adenosine, EDT, Science, Patent, Patient, Liver, Eon, Metabolism, Uridine, Q&A, Pharmaceutical industry

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
  • At March 31, 2024, ProQR held cash and cash equivalents and short term financial assets of €102.7 million, compared to €118.9 million cash and cash equivalents at December 31, 2023.
  • General and administrative costs were €3.5 million for the quarter ended March 31, 2024 compared to €4.0 million for the same period last year.
  • For further financial information for the period ended March 31, 2024, please refer to the Q1 financial report filing.

Rogers $1M Season of Canada’s Got Talent: CGT Reveals the First Six Performers Heading to the Finale, May 14 on Citytv

Retrieved on: 
Mittwoch, Mai 8, 2024
Hatred, Prince Albert, Humour, ABBA, MAT, MYM, AB, CGT, Mission, Was, Kardinal Offishall, Toronto Maple Leafs, CIBC, Sterling, TROY, Lilly, Sand, Entertainment

TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- On tonight’s episode of Canada’s Got Talent on Citytv, the #CGT judges – Howie Mandel, Lilly Singh, Trish Stratus, Kardinal Offishall – and host Lindsay Ell selected the first six of eight acts moving on to the live two-hour finale, airing Tuesday, May 14 at 8 p.m. ET / 5 p.m. PT on Citytv and Citytv+. They are:

Key Points: 
  • ET / 5 p.m. PT on Citytv and Citytv+.
  • ET / 1 a.m. PT to vote two additional acts from tonight’s episode into the finale at www.Citytv.com/vote .
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 8, 2024
LDLR, Verve, Safety, Pharmacokinetics, ASCVD, LNP, Eli Lilly, Moyamoya disease, N-Acetylgalactosamine, RNA, Aortic stenosis, Stroke, Cell, Conference, Research, Webcast, PCSK9, IND, Administration, Potential, Research and development, Patient, Liver, Gene, CAD, Society, Medicine, ANGPTL3, Lilly, Cardiovascular disease, CTAS, Therapy, Asialoglycoprotein receptor, G&A, LPA, Pharmaceutical industry

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the quarter ended March 31, 2024.

Key Points: 
  • Cash Position: Verve ended the first quarter of 2024 with $606.4 million in cash, cash equivalents, and marketable securities.
  • Collaboration Revenue: Collaboration revenue was $5.7 million for the first quarter of 2024, compared to $1.4 million for the first quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $14.2 million for the first quarter of 2024, compared to $12.6 million for the first quarter of 2023.
  • Stock-based compensation expense included in G&A expenses was $4.7 million and $3.5 million for the first quarter of 2024 and 2023, respectively.

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
Dienstag, Mai 7, 2024
Pancreatic cancer, ITK, Hidradenitis suppurativa, Research, ACRS, Webcast, Patient, Rheumatoid arthritis, Lilly, Interim, Atopic dermatitis, Therapy, G&A, Pharmaceutical industry

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
  • In September 2023, Aclaris reported positive results from its Phase 1 multiple ascending dose (MAD) trial of ATI-2138.
  • Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023.
  • Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023.

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Retrieved on: 
Montag, Mai 6, 2024
Chromatin, Protein, SMARCA4, BRG1, Security, Research, SMARCA2, IND, Prostate cancer, LDAC, Acetyltransferase, BRM, AACR, Lung cancer, Multiple myeloma, AML, CBP, ARID1B, Lilly, Complex, Merck, NSCLC, DLBCL, ARID1A, Survival, Thrombocytopenia, Therapy, Gene expression, Biology, Cancer, Prostate, Data, Patient, Selective, SWI/SNF, Neoplasm, MDS, Anemia, Pharmaceutical industry

In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.

Key Points: 
  • In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.
  • In April 2024, Foghorn hosted the first Future of Disease and Chromatin Regulation Summit at the Foghorn corporate headquarters in Cambridge, Massachusetts.
  • In April 2024, Foghorn appointed Kristian Humer as Chief Financial Officer.
  • In April, Foghorn presented new pharmacodynamic and pharmacokinetic preclinical data at the 2024 AACR Annual Meeting highlighting:
    No observed thrombocytopenia in vivo.

Redwire Pioneering Biopharma Production in Space by Successfully Bioprinting Live Human Heart Tissue and Delivering Second Batch of PIL-BOX Pharmaceutical Crystal Experiments

Retrieved on: 
Mittwoch, Mai 8, 2024
Other Health, General Health, Pharmaceutical, Technology, Satellite, Science, Cardiology, Aerospace, Other Technology, Manufacturing, Other Science, Health, BFF, Blood, RDW, ISS, Corporation, International Space Station, Eli Lilly and Company, Research, Life, Patient, Lilly, Multimedia, Drug discovery, PIL

The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire’s PIL-BOX platform.

Key Points: 
  • The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire’s PIL-BOX platform.
  • View the full release here: https://www.businesswire.com/news/home/20240507667003/en/
    Live human heart tissue bioprinted with Redwire's BioFabrication Facility onboard the International Space Station.
  • Redwire’s second batch of returned PIL-BOX experiments comprised of 36 crystal experiments, which included various crystal molecules designed for pharmaceutical use, with antiviral, antifungal, and antiseizure applications.
  • Redwire has developed 20 research facilities for crewed spacecraft, with 10 currently aboard the ISS supporting world-leading research and manufacturing missions.

Hall of Fame U.S. Soccer Player Kristine Lilly to Join Hundreds of MNA Nurses and Healthcare Professionals at the State House May 8 for Advocacy Day During National Nurses Week

Retrieved on: 
Freitag, Mai 3, 2024
National Nurses United, Organization, Kristine Lilly, Silver, Sport, Book, Medfield, Massachusetts, RNS, Workplace violence, Commonwealth, Olympic Games, Statehouse, Workplace, Legislature, ICU, Speech, Grand Staircase, Gold, Patient, Legislation, Athlete, Football, Lilly, Multimedia, MNA, Health, Female, Excellence, Nursing

BOSTON, May 3, 2024 /PRNewswire/ -- Hundreds of nurses and healthcare professionals will flood the State House on May 8, marking National Nurses Week with a Day of Advocacy focused on protecting patients, healthcare workers, and essential healthcare services. They will be joined by Kristine Lilly, one of the most accomplished athletes in women's soccer history, a teamwork expert, and an advocate for pay equity in women's sports.

Key Points: 
  • The Massachusetts Nurses Association will also release its annual "State of Nursing in Massachusetts" survey ahead of Advocacy Day, on Monday, May 6.
  • It will provide critical insight into care quality and nursing practice challenges, and the legislative solutions nurses say will ensure safe, accessible patient care.
  • "I am excited to join hundreds of MNA nurses and healthcare professionals as they urge their elected officials to protect patients, workers, and essential healthcare services," Kristine Lilly said.
  • Lilly was inducted into the US Olympic Hall of Fame in 2012 and the US Soccer Hall of Fame in 2014.

Gildred Companies Announces Brook Logan as Chief Operating Officer

Retrieved on: 
Dienstag, April 30, 2024
Emerald, Sale, San Diego State University, CFO, Human resources, Accounting, Eli Lilly, Growth, AppFolio, Chairperson, IPO, Acquisition, Gildred, Lilly, SAN, Management

SAN DIEGO, April 30, 2024 /PRNewswire-PRWeb/ -- Gildred Companies is pleased to announce that Brook Logan has been named Chief Operating Officer (COO). Logan has served in the role of Chief Financial Officer (CFO) since joining the Gildred Team in 2022.

Key Points: 
  • Logan will focus on optimizing operations, financial direction and leadership
    SAN DIEGO, April 30, 2024 /PRNewswire-PRWeb/ -- Gildred Companies is pleased to announce that Brook Logan has been named Chief Operating Officer (COO).
  • Logan has served in the role of Chief Financial Officer (CFO) since joining the Gildred Team in 2022.
  • "We are thrilled to name Brook Logan Chief Operating Officer.
  • "We are thrilled to name Brook Logan Chief Operating Officer.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
Dienstag, April 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.